<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="950">
  <stage>Registered</stage>
  <submitdate>27/10/2005</submitdate>
  <approvaldate>27/10/2005</approvaldate>
  <nctid>NCT00246675</nctid>
  <trial_identification>
    <studytitle>Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.</studytitle>
    <scientifictitle>Frusemide Infusion for the Prevention of Deterioration of Renal Function in Post Cardiac Surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2002.167</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal Impairment After Cardiac Surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Frusemide

Other: Standard Care - Patients will only receive frusemide as per the treating physicians treatment

Other: Intervention - Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour


Treatment: drugs: Frusemide


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The incidence of increase in creatinine of 0.05 mmol/L or greater in the first 72 hours after cardiac surgery.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. The maximum change in serum creatinine from baseline value during the first 7 days of hospital stay.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Incidence of renal failure requiring any form of renal replacement therapy.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Duration of post-operative hospital and ICU stay.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. The maximum Sequential Organ Failure Assessment (SOFA) score in the first 7 days of hospital stay.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients admitted for cardiac surgery will be assessed for eligibility. Participants
        will be approached for inclusion, from the pre-admission clinics and wards of the
        Cardiothoracic surgery unit. Potential participants will be identified by the daily review
        of planned cardiothoracic surgery schedule.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Already in established dialysis dependent chronic renal failure.

          2. Known allergy to frusemide

          3. Age &lt; 18 years

          4. Pregnant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Intensive Care Unit, Royal Melbourne Hospital - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the project is to test whether or not the commonly used medication frusemide,
      given after heart surgery, and aiming to increase urinary output can have an effect on kidney
      function.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00246675</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John F Cade</name>
      <address>Royal Melbourne Hospital, Intensive Care Unit</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>